Panobinostat Approved for Multiple Myeloma.
[No authors listed. Cancer Discov. 2015 Mar 23. [Epub ahead of print].

American Society of Hematology Annual Meeting 2014: highlights in multiple myeloma.
Glavey SV et al. Expert Rev Hematol. 2015 Mar 24:1-3. [Epub ahead of print].

Recent advances in multiple myeloma.
Kohgo Y et al. Int J Clin Oncol. 2015 Mar 20. [Epub ahead of print].

Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.
Arikian SR et al. Curr Med Res Opin. 2015 Mar 18:1-33. [Epub ahead of print].

Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma.
Fiala MA et al. Biol Blood Marrow Transplant. 2015 Mar 11. pii: S1083-8791(15)00177-9. doi: 10.1016/j.bbmt.2015.03.005. [Epub ahead of print].

Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the ASBMT.
Shah N et al. Biol Blood Marrow Transplant. 2015 Mar 10. pii: S1083-8791(15)00174-3. doi: 10.1016/j.bbmt.2015.03.002. [Epub ahead of print].

Health-related quality of life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.
Delforge M et al. Haematologica. 2015 Mar 13. pii: haematol.2014.120121. [Epub ahead of print].

The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents.
Gay F et al. Drugs. 2015 Mar;75(4):367-75. doi: 10.1007/s40265-015-0367-0.

MR Imaging and PET/CT in Diagnosis and Management of Multiple Myeloma.
Ferraro R et al. Radiographics. 2015 Mar-Apr;35(2):438-54. doi: 10.1148/rg.352140112.

Optimized patient-trajectory for patients undergoing treatment with high-dose chemotherapy and autologous stem cell transplantation.
Bartels FR et al. Acta Oncol. 2015 Mar 11:1-9. [Epub ahead of print].

Case records of the Massachusetts General Hospital. Case 8-2015. A 68-year-old man with multiple myeloma, skin tightness, arthralgias, and edema.
Wigley F et al. N Engl J Med. 2015 Mar 12;372(11):1056-67. doi: 10.1056/NEJMcpc1409840.

Is This the Time to Introduce Minimal Residual Disease in Multiple Myeloma Clinical Practice?
Paiva B et al. Clin Cancer Res. 2015 Mar 9. pii: clincanres.2841.2014. [Epub ahead of print].

Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma.
Lendvai N et al. Bone Marrow Transplant. 2015 Mar 9. doi: 10.1038/bmt.2015.5. [Epub ahead of print].

G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization inmultiple myeloma: effectiveness, safety and cost analysis.
Antar A et al. Bone Marrow Transplant. 2015 Mar 9. doi: 10.1038/bmt.2015.23. [Epub ahead of print].

Exercise compliance among patients with multiple myeloma undergoing chemotherapy: a retrospective study.
Shallwani S et al. Support Care Cancer. 2015 Mar 6. [Epub ahead of print].

Experimental design and statistical analysis for three-drug combination studies.
Fang HB et al. Stat Methods Med Res. 2015 Mar 4. pii: 0962280215574320. [Epub ahead of print].

Optimizing quality of life in multiple myeloma patients: current options, challenges and recommendations.
Maes H et al. Expert Rev Hematol. 2015 Mar 5:1-12. [Epub ahead of print].

Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group.
Quach H et al. Intern Med J. 2015 Mar;45(3):335-43. doi: 10.1111/imj.12688.

The relative length of the patient and the primary care interval in patients with 28 common and rarer cancers.
Lyratzopoulos G et al. Br J Cancer. 2015 Mar 3. doi: 10.1038/bjc.2015.40. [Epub ahead of print].

CCR 20th Anniversary Commentary: In the Beginning, There Was PS-341.
Teicher BA et al. Clin Cancer Res. 2015 Mar 1;21(5):939-41. doi: 10.1158/1078-0432.CCR-14-2549.

Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myelomapatients in the era of novel agent therapy.
Phipps C et al. Bone Marrow Transplant. 2015 Mar 2. doi: 10.1038/bmt.2015.13. [Epub ahead of print].

Carfilzomib: A second-generation proteasome inhibitor for the treatment of multiple myeloma.
McBride A et al. Am J Health Syst Pharm. 2015 Mar 1;72(5):353-360.